Responses
Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0377 Differences in Baseline Predictive Factors for Remission at 52 Weeks by Concomitant MTX Use during Tocilizumab Treatment Using Propensity Score Matched Groups
Compose a Response to This Article
Other responses
No responses have been published for this article.